MedDataX Logo

A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

NCT ID: NCT00750620

Last Updated: 2013-09-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-09-30

Study Completion Date

2009-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to assess and compare the pharmacokinetic properties of YM178 in normal subjects and those with mild, moderate and severe renal impairment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function

NCT01372826

Renal Impairment
COMPLETED PHASE1

Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects

NCT01459250

Renal Impairment
COMPLETED PHASE1

PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function

NCT04656795

Renal Impairment Normal Renal Function
COMPLETED PHASE1

Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function

NCT02508506

Renal Impairment
COMPLETED PHASE1

Examination of Plasma Concentrations and Safety in Chronic Kidney Disease Patients Undergoing Hemodialysis

NCT01872026

Patients on Stable Chronic Maintenance Dialysis Who Are Receiving Hemodialysis Therapy Pharmacodynamics of ASP7991 Pharmacokinetics of ASP7991
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1. Severe renal impairment

severe renal impairment

Group Type EXPERIMENTAL

YM178

Intervention Type DRUG

oral

2. Moderate renal impairment

moderate renal impairment

Group Type EXPERIMENTAL

YM178

Intervention Type DRUG

oral

3. Mild renal impairment

mild renal impairment

Group Type EXPERIMENTAL

YM178

Intervention Type DRUG

oral

4. Normal renal function

normal renal function

Group Type EXPERIMENTAL

YM178

Intervention Type DRUG

oral

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

YM178

oral

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

mirabegron

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* good health other than renal impairment
* body mass index (BMI) between 18 and 40 kg/m2

Exclusion Criteria

* subject with renal impairment has not been on stable dose of concomitant medication for at least 2 weeks
* subject has liver enzyme abnormalities
Minimum Eligible Age

18 Years

Maximum Eligible Age

79 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Astellas Pharma Inc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Central Contact

Role: STUDY_DIRECTOR

Astellas Pharma Global Development

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Anaheim, California, United States

Site Status

Miami, Florida, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Dickinson J, Lewand M, Sawamoto T, Krauwinkel W, Schaddelee M, Keirns J, Kerbusch V, Moy S, Meijer J, Kowalski D, Morton R, Lasseter K, Riff D, Kupcova V, van Gelderen M. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron. Clin Drug Investig. 2013 Jan;33(1):11-23. doi: 10.1007/s40261-012-0031-3.

Reference Type BACKGROUND
PMID: 23208320 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

178-CL-038

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.
NCT06586216 COMPLETED PHASE1
An Open-label, Parallel-group Study to Determine the Pharmacokinetics of a Single Dose of AFQ056 in Subjects With Renal Impairment Compared to Healthy Subjects
NCT01442259 COMPLETED PHASE1
To Compare the Pharmacokinetics of Avanafil in Subjects With Mild and Moderate Renal Impairment to Subjects With Normal Renal Function.
NCT01054261 COMPLETED PHASE1
ASP8825 - Pharmacokinetics Study in Patients With Impaired Renal Function and Haemodialysis
NCT02629224 COMPLETED PHASE1
A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function
NCT04699877 COMPLETED PHASE1
Pharmacokinetics Study in Patients With Impaired Renal Function and Subjects With Normal Renal Function
NCT02603497 COMPLETED PHASE1
A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment
NCT05200286 COMPLETED PHASE1
Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis
NCT05624723 COMPLETED PHASE1
A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis
NCT00505037 COMPLETED PHASE2
Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis
NCT05099445 COMPLETED PHASE1
The Pharmacokinetics of MK-7145 Following Single Dose Administration in Participants With Moderate Renal Insufficiency (MK-7145-018)
NCT01832103 WITHDRAWN PHASE1
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
NCT07165015 RECRUITING PHASE1
Single-Dose PK Study of GBT440 in Subjects With Renal Impairment
NCT03161015 COMPLETED PHASE1
A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780
NCT06592482 COMPLETED PHASE1
Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004)
NCT04678505 TERMINATED PHASE1
A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004
NCT06742762 COMPLETED PHASE1
Study of ALXN2050 in Participants With Renal Impairment
NCT04623710 COMPLETED PHASE1
Comparative Evaluation of Pharmacokinetics After CKD-501 Between Renal Impaired and Normal Renal Function Subjects
NCT02007941 COMPLETED PHASE1
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
NCT06039254 UNKNOWN PHASE1
Pharmacokinetics (PK) of Dalfampridine-ER 7.5 mg BID in Healthy Volunteers and Subjects With Mild or Moderate Renal Impairment
NCT01316055 COMPLETED PHASE1
A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants
NCT05363215 COMPLETED PHASE1
Pharmacokinetics in Subjects With Renal Impairment
NCT01504165 COMPLETED PHASE1
PF-04634817 Renal Impairment Study
NCT01791855 COMPLETED PHASE1
A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function
NCT01359579 TERMINATED PHASE1
A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney Transplantation
NCT01279538 COMPLETED PHASE1